BCDA vs. CHRO, ONVO, COEP, IKT, GENE, SRNE, TTNP, CELZ, FRTX, and PALI
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Chromocell Therapeutics (CHRO), Organovo (ONVO), Coeptis Therapeutics (COEP), Inhibikase Therapeutics (IKT), Genetic Technologies (GENE), Sorrento Therapeutics (SRNE), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), Fresh Tracks Therapeutics (FRTX), and Palisade Bio (PALI). These companies are all part of the "biological products, except diagnostic" industry.
Chromocell Therapeutics (NYSE:CHRO) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
BioCardia has a consensus price target of $4.00, indicating a potential upside of 936.27%. Given Chromocell Therapeutics' higher probable upside, analysts clearly believe BioCardia is more favorable than Chromocell Therapeutics.
In the previous week, BioCardia had 3 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 3 mentions for BioCardia and 0 mentions for Chromocell Therapeutics. Chromocell Therapeutics' average media sentiment score of 0.13 beat BioCardia's score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.
78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BioCardia received 10 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users.
Chromocell Therapeutics has higher earnings, but lower revenue than BioCardia.
Chromocell Therapeutics has a net margin of 0.00% compared to Chromocell Therapeutics' net margin of -2,425.79%. BioCardia's return on equity of 0.00% beat Chromocell Therapeutics' return on equity.
Summary
BioCardia beats Chromocell Therapeutics on 7 of the 11 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
